Notre offre FCPI Truffle InnoCroissance 2015 et Mandat de gestion

The fast pace of innovation in IT offers compelling investment opportunities

Truffle Capital is a pioneer investor in the exciting field of Energy

Biotechnology has radically transformed medicine over the past 25 years


Vexim, set up in 2006 as a spin-off from Teknimed, a French leader in orthopedic cements, specializes in minimally-invasive solutions for treatment of the causes and consequences of vertebral damage. It has notably developed the SpineJack® – a system for controlled anatomical repair of vertebral compression fractures (VCF).

Truffle initially invested in Vexim in 2006. Since then, Vexim has successfully treated hundreds of patients and obtained the CE mark for the SpineJack. Vexim was listed on Alternext in May 2012 (ALVXM).

Truffle Capital board members: Dr. Philippe Pouletty

Interview de Vincent Gardès, Directeur Général de Vexim sur le bilan 2014, l’évolution des produits et les perspectives, 24/03/2015 – La bourse et la

10 avril 2012 – Présentation de Vexim, spécialisée dans la chirurgie innovante du dos